Abstract:
Breast cancer remains a leading cause of mortality in women worldwide, emphasizing the need for novel, safe, and effective therapeutic strategies. This study investigates the potential of four natural bioactive compounds—Berberine, Curcumin, Withaferin A, and Ellagic Acid—to target critical breast cancer biomarkers, including BCL-2, PD-L1, CDK4/6, and FGFR, which are involved in tumor progression, immune evasion, and cell cycle regulation.
Using in silico approaches, including pharmacokinetic (ADME) profiling, molecular docking, and molecular dynamics simulations, we evaluated the binding affinities, stability, and drug-likeness of these compounds. Results indicate that Berberine and Ellagic Acid exhibit strong interactions with the selected targets, with binding affinities of −9.3 kcal/mol for BCL-2 and −9.8 kcal/mol for PD-L1, respectively, and form stable protein–ligand complexes over 100 ns simulations. ADME profiling further highlights their favorable absorption and solubility, suggesting suitability for clinical applications.
These findings underscore the potential of Berberine and Ellagic Acid as multi-target natural inhibitors for breast cancer therapy, offering promising leads for further experimental validation and development of safer, cost-effective anticancer strategies.
Biography:
Dr. Saba Beigh is an Associate Professor of Toxicology and Pharmacology at Al-Baha University, Saudi Arabia. She obtained her Ph.D. in Toxicology and Pharmacology from Jamia Hamdard University, India, and completed her postdoctoral training in Nanotoxicology at the University of Strasbourg, France. Her research focuses on pulmonary toxicology, nanotoxicology, oxidative stress, immunopharmacology, and computational pharmacology. She has authored numerous publications in peer-reviewed journals and has been honored with awards including the EUROTOX Best Poster Award and the CSIR-SRF Fellowship.
Copyright 2024 Mathews International LLC All Rights Reserved
